New strategy for safer CAR T cell therapy in lymphomas.

Researchers at the University of Cologne have developed a new strategy to improve the effectiveness and safety of chimeric antigen receptor T cell (CAR T cell) therapy for aggressive lymphomas and blood cancer. CAR T cell therapy involves genetically engineering immune cells to target proteins on tumor cells. The researchers used two CAR constructs with different target proteins, CD19 and CD80/CD86, to activate the T cells against the tumor cells. This approach allows for more effective cancer cell fighting while sparing healthy B lymphocytes. The next step is to conduct clinical trials to test this strategy in patients with B-cell lymphoma. [Extracted from the article]